Key clinical point: In a cohort of patients with early rheumatoid arthritis (RA), illness perceptions and suboptimal psychosocial well-being were associated with a lower likelihood of sustained remission.

Major finding: Among patients who were had a disease activity score in 28 joints-C-reactive protein remission at week 16, those with a low vs. high psychosocial burden profile showed a significantly longer time to first loss-of-remission (hazard ratio 0.51; P < .001).

Study details: This was a post hoc analysis of the CareRA trial involving 379 patients with early RA who received methotrexate ± additional conventional synthetic disease-modifying antirheumatic drugs or glucocorticoids.

Disclosures: This study was supported in part by a Strategic Basic Research Fellowship grant from Fonds Wetenschappelijk Onderzoek. All the authors declared no conflicts of interest.

Source: Doumen M et al. Arthritis Care Res (Hoboken). 2021 (Dec 20). Doi: 10.1002/acr.24847.

Key clinical point: In a cohort of patients with early rheumatoid arthritis (RA), illness perceptions and suboptimal psychosocial well-being were associated with a lower likelihood of sustained remission.

Major finding: Among patients who were had a disease activity score in 28 joints-C-reactive protein remission at week 16, those with a low vs. high psychosocial burden profile showed a significantly longer time to first loss-of-remission (hazard ratio 0.51; P < .001).

Study details: This was a post hoc analysis of the CareRA trial involving 379 patients with early RA who received methotrexate ± additional conventional synthetic disease-modifying antirheumatic drugs or glucocorticoids.

Disclosures: This study was supported in part by a Strategic Basic Research Fellowship grant from Fonds Wetenschappelijk Onderzoek. All the authors declared no conflicts of interest.

Source: Doumen M et al. Arthritis Care Res (Hoboken). 2021 (Dec 20). Doi: 10.1002/acr.24847.

Key clinical point: In a cohort of patients with early rheumatoid arthritis (RA), illness perceptions and suboptimal psychosocial well-being were associated with a lower likelihood of sustained remission.

Major finding: Among patients who were had a disease activity score in 28 joints-C-reactive protein remission at week 16, those with a low vs. high psychosocial burden profile showed a significantly longer time to first loss-of-remission (hazard ratio 0.51; P < .001).

Study details: This was a post hoc analysis of the CareRA trial involving 379 patients with early RA who received methotrexate ± additional conventional synthetic disease-modifying antirheumatic drugs or glucocorticoids.

Disclosures: This study was supported in part by a Strategic Basic Research Fellowship grant from Fonds Wetenschappelijk Onderzoek. All the authors declared no conflicts of interest.

Source: Doumen M et al. Arthritis Care Res (Hoboken). 2021 (Dec 20). Doi: 10.1002/acr.24847.

Key clinical point: Celecoxib appeared to be relatively safer compared with nonselective nonsteroidal anti-inflammatory drugs (NSAID) or placebo in patients with rheumatoid arthritis (RA), regardless of dose or duration.

Major finding: Celecoxib was associated with a lower risk for all-cause mortality (risk ratio [RR] 0.81; 95% CI 0.66-0.98) and cardiovascular morality (RR 0.75; 95% CI 0.57-0.99) compared with NSAIDs and a similar risk for all-cause mortality (RR 0.92; 95% CI 0.26-3.27) and cardiovascular morality (RR 3.02; 95% CI 0.36-25.27) compared with placebo.

Study details: Findings are from a meta-analysis of 21 randomized clinical studies that compared cardiovascular safety of celecoxib with NSAIDs or placebo in patients with RA or osteoarthritis.

Disclosures: This study was supported by the National Natural Science Foundation project and others. No competing interests were declared.

Source: Cheng BR et al. PLoS One. 2021;16(12):e0261239 (Dec 21). Doi:  10.1371/journal.pone.0261239.

Key clinical point: Celecoxib appeared to be relatively safer compared with nonselective nonsteroidal anti-inflammatory drugs (NSAID) or placebo in patients with rheumatoid arthritis (RA), regardless of dose or duration.

Major finding: Celecoxib was associated with a lower risk for all-cause mortality (risk ratio [RR] 0.81; 95% CI 0.66-0.98) and cardiovascular morality (RR 0.75; 95% CI 0.57-0.99) compared with NSAIDs and a similar risk for all-cause mortality (RR 0.92; 95% CI 0.26-3.27) and cardiovascular morality (RR 3.02; 95% CI 0.36-25.27) compared with placebo.

Study details: Findings are from a meta-analysis of 21 randomized clinical studies that compared cardiovascular safety of celecoxib with NSAIDs or placebo in patients with RA or osteoarthritis.

Disclosures: This study was supported by the National Natural Science Foundation project and others. No competing interests were declared.

Source: Cheng BR et al. PLoS One. 2021;16(12):e0261239 (Dec 21). Doi:  10.1371/journal.pone.0261239.

Key clinical point: Celecoxib appeared to be relatively safer compared with nonselective nonsteroidal anti-inflammatory drugs (NSAID) or placebo in patients with rheumatoid arthritis (RA), regardless of dose or duration.

Major finding: Celecoxib was associated with a lower risk for all-cause mortality (risk ratio [RR] 0.81; 95% CI 0.66-0.98) and cardiovascular morality (RR 0.75; 95% CI 0.57-0.99) compared with NSAIDs and a similar risk for all-cause mortality (RR 0.92; 95% CI 0.26-3.27) and cardiovascular morality (RR 3.02; 95% CI 0.36-25.27) compared with placebo.

Study details: Findings are from a meta-analysis of 21 randomized clinical studies that compared cardiovascular safety of celecoxib with NSAIDs or placebo in patients with RA or osteoarthritis.

Disclosures: This study was supported by the National Natural Science Foundation project and others. No competing interests were declared.

Source: Cheng BR et al. PLoS One. 2021;16(12):e0261239 (Dec 21). Doi:  10.1371/journal.pone.0261239.

Key clinical point: Patients with rheumatoid arthritis (RA) experienced robust pain reduction with baricitinib, irrespective of opioid use.

Major finding: Compared with placebo, pain reduction was significantly greater at all time points, starting as early as week 1 (all P < .05) in both opioid users and nonusers receiving 4 mg baricitinib and only in opioid users receiving 2 mg baricitinib. Opioid nonusers receiving 2 mg baricitinib showed greater pain relief than placebo starting at week 4 (P < .05).

Study details: This was a post hoc analysis of 3 randomized controlled trials (RA-BEAM, RA-BUILD, and RA-BEACON) involving patients with RA with an inadequate response to either methotrexate, conventional disease-modifying antirheumatic drugs, or at least 1 tumor necrosis factor inhibitor, who were randomly assigned to either placebo, baricitinib (2 mg/4 mg), or adalimumab (40 mg) in addition to background therapy.

Disclosures: This study was funded by Eli Lilly under license from Incyte Corporation. The authors declared no conflict of interests.

Source: Pope JE et al. ACR Open Rheumatol. 2021 (Dec 16). Doi: 10.1002/acr2.11380.

Key clinical point: Patients with rheumatoid arthritis (RA) experienced robust pain reduction with baricitinib, irrespective of opioid use.

Major finding: Compared with placebo, pain reduction was significantly greater at all time points, starting as early as week 1 (all P < .05) in both opioid users and nonusers receiving 4 mg baricitinib and only in opioid users receiving 2 mg baricitinib. Opioid nonusers receiving 2 mg baricitinib showed greater pain relief than placebo starting at week 4 (P < .05).

Study details: This was a post hoc analysis of 3 randomized controlled trials (RA-BEAM, RA-BUILD, and RA-BEACON) involving patients with RA with an inadequate response to either methotrexate, conventional disease-modifying antirheumatic drugs, or at least 1 tumor necrosis factor inhibitor, who were randomly assigned to either placebo, baricitinib (2 mg/4 mg), or adalimumab (40 mg) in addition to background therapy.

Disclosures: This study was funded by Eli Lilly under license from Incyte Corporation. The authors declared no conflict of interests.

Source: Pope JE et al. ACR Open Rheumatol. 2021 (Dec 16). Doi: 10.1002/acr2.11380.

Key clinical point: Patients with rheumatoid arthritis (RA) experienced robust pain reduction with baricitinib, irrespective of opioid use.

Major finding: Compared with placebo, pain reduction was significantly greater at all time points, starting as early as week 1 (all P < .05) in both opioid users and nonusers receiving 4 mg baricitinib and only in opioid users receiving 2 mg baricitinib. Opioid nonusers receiving 2 mg baricitinib showed greater pain relief than placebo starting at week 4 (P < .05).

Study details: This was a post hoc analysis of 3 randomized controlled trials (RA-BEAM, RA-BUILD, and RA-BEACON) involving patients with RA with an inadequate response to either methotrexate, conventional disease-modifying antirheumatic drugs, or at least 1 tumor necrosis factor inhibitor, who were randomly assigned to either placebo, baricitinib (2 mg/4 mg), or adalimumab (40 mg) in addition to background therapy.

Disclosures: This study was funded by Eli Lilly under license from Incyte Corporation. The authors declared no conflict of interests.

Source: Pope JE et al. ACR Open Rheumatol. 2021 (Dec 16). Doi: 10.1002/acr2.11380.

Key clinical point: Significant improvement in patient-reported outcomes was observed with filgotinib in patients with rheumatoid arthritis (RA) with an insufficient response to methotrexate or biological disease-modifying antirheumatic drugs (DMARD) and those who were methotrexate-naive.

Major finding: Filgotinib at doses of 200 mg or 100 mg in combination with methotrexate/conventional synthetic DMARDs or 200 mg filgotinib monotherapy demonstrated a significant improvement in the health-related quality of life, fatigue, and assessments of disease activity and work impairment vs. comparators (all P < .05).

Study details: This was a post hoc analysis of phase 3 studies including patients with RA with an inadequate response to methotrexate (FINCH 1) or biological DMARDs (FINCH 2) and those who were methotrexate-naive (FINCH 3).

Disclosures: This study was supported by Gilead Sciences, Inc., Foster City, CA. SJ Lee, L Ye, and H Hu reported being employees and shareholders of Gilead Sciences. All the other authors disclosed receiving grants/research support and speaker/consultancy fees from various companies including Gilead Sciences.

Source: Bingham CO III et al. Arthritis Res Ther. 2022;24:11 (Jan 3). Doi: 10.1186/s13075-021-02677-7.

Key clinical point: Significant improvement in patient-reported outcomes was observed with filgotinib in patients with rheumatoid arthritis (RA) with an insufficient response to methotrexate or biological disease-modifying antirheumatic drugs (DMARD) and those who were methotrexate-naive.

Major finding: Filgotinib at doses of 200 mg or 100 mg in combination with methotrexate/conventional synthetic DMARDs or 200 mg filgotinib monotherapy demonstrated a significant improvement in the health-related quality of life, fatigue, and assessments of disease activity and work impairment vs. comparators (all P < .05).

Study details: This was a post hoc analysis of phase 3 studies including patients with RA with an inadequate response to methotrexate (FINCH 1) or biological DMARDs (FINCH 2) and those who were methotrexate-naive (FINCH 3).

Disclosures: This study was supported by Gilead Sciences, Inc., Foster City, CA. SJ Lee, L Ye, and H Hu reported being employees and shareholders of Gilead Sciences. All the other authors disclosed receiving grants/research support and speaker/consultancy fees from various companies including Gilead Sciences.

Source: Bingham CO III et al. Arthritis Res Ther. 2022;24:11 (Jan 3). Doi: 10.1186/s13075-021-02677-7.

Key clinical point: Significant improvement in patient-reported outcomes was observed with filgotinib in patients with rheumatoid arthritis (RA) with an insufficient response to methotrexate or biological disease-modifying antirheumatic drugs (DMARD) and those who were methotrexate-naive.

Major finding: Filgotinib at doses of 200 mg or 100 mg in combination with methotrexate/conventional synthetic DMARDs or 200 mg filgotinib monotherapy demonstrated a significant improvement in the health-related quality of life, fatigue, and assessments of disease activity and work impairment vs. comparators (all P < .05).

Study details: This was a post hoc analysis of phase 3 studies including patients with RA with an inadequate response to methotrexate (FINCH 1) or biological DMARDs (FINCH 2) and those who were methotrexate-naive (FINCH 3).

Disclosures: This study was supported by Gilead Sciences, Inc., Foster City, CA. SJ Lee, L Ye, and H Hu reported being employees and shareholders of Gilead Sciences. All the other authors disclosed receiving grants/research support and speaker/consultancy fees from various companies including Gilead Sciences.

Source: Bingham CO III et al. Arthritis Res Ther. 2022;24:11 (Jan 3). Doi: 10.1186/s13075-021-02677-7.

Key clinical point: Every 1 in 6 individuals with rheumatoid arthritis (RA) develop interstitial lung disease (ILD) within 20 years, with RA-associated ILD (RA-ILD), even when asymptomatic and radiologically limited, being significantly associated with shorter survival.

Major finding: The cumulative incidence of RA-ILD was 15.3% at 20 years after RA diagnosis, with mortality being higher in patients with RA-ILD vs. matched RA comparators (hazard ratio 2.42; 95% CI 1.32-4.41).

Study details: This was a population-based cohort study involving 645 patients with incident RA.

Disclosures: This study was funded by the National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases, and others. R Vassallo and JM Davis III reported receiving research grants from various sources.

Source: Samhouri BF et al. Arthritis Care Res (Hoboken). 2022 (Jan 7). Doi: 10.1002/acr.24856.

Key clinical point: Every 1 in 6 individuals with rheumatoid arthritis (RA) develop interstitial lung disease (ILD) within 20 years, with RA-associated ILD (RA-ILD), even when asymptomatic and radiologically limited, being significantly associated with shorter survival.

Major finding: The cumulative incidence of RA-ILD was 15.3% at 20 years after RA diagnosis, with mortality being higher in patients with RA-ILD vs. matched RA comparators (hazard ratio 2.42; 95% CI 1.32-4.41).

Study details: This was a population-based cohort study involving 645 patients with incident RA.

Disclosures: This study was funded by the National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases, and others. R Vassallo and JM Davis III reported receiving research grants from various sources.

Source: Samhouri BF et al. Arthritis Care Res (Hoboken). 2022 (Jan 7). Doi: 10.1002/acr.24856.

Key clinical point: Every 1 in 6 individuals with rheumatoid arthritis (RA) develop interstitial lung disease (ILD) within 20 years, with RA-associated ILD (RA-ILD), even when asymptomatic and radiologically limited, being significantly associated with shorter survival.

Major finding: The cumulative incidence of RA-ILD was 15.3% at 20 years after RA diagnosis, with mortality being higher in patients with RA-ILD vs. matched RA comparators (hazard ratio 2.42; 95% CI 1.32-4.41).

Study details: This was a population-based cohort study involving 645 patients with incident RA.

Disclosures: This study was funded by the National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases, and others. R Vassallo and JM Davis III reported receiving research grants from various sources.

Source: Samhouri BF et al. Arthritis Care Res (Hoboken). 2022 (Jan 7). Doi: 10.1002/acr.24856.

Key clinical point: In patients with rheumatoid arthritis (RA), sleep problems are more extensively related to pain and functional impairment than disease duration.

Major finding: The likelihood of having problems with at least 1 or more sleep domains increased slightly with the disease duration (adjusted odds ratio 1.04; 95% CI 1.02-1.07). High-grade pain and high Health Assessment Questionnaire (HAQ) level were associated with increased sleep problems by approximately 3-9-fold and 4-8-fold compared with low-grade pain and low HAQ level, respectively.

Study details: This was an analysis of 4,131 observations from 3,265 patients with newly diagnosed RA whose data on sleep over 12 years from diagnosis were available.

Disclosures: This study was supported by Karolinska Institutet and Reumatikerförbundet. All the authors declared no competing interests.

Source: Lyne L et al. RMD Open. 2022;8:e001800 (Jan 5). Doi: 10.1136/rmdopen-2021-001800.

Key clinical point: In patients with rheumatoid arthritis (RA), sleep problems are more extensively related to pain and functional impairment than disease duration.

Major finding: The likelihood of having problems with at least 1 or more sleep domains increased slightly with the disease duration (adjusted odds ratio 1.04; 95% CI 1.02-1.07). High-grade pain and high Health Assessment Questionnaire (HAQ) level were associated with increased sleep problems by approximately 3-9-fold and 4-8-fold compared with low-grade pain and low HAQ level, respectively.

Study details: This was an analysis of 4,131 observations from 3,265 patients with newly diagnosed RA whose data on sleep over 12 years from diagnosis were available.

Disclosures: This study was supported by Karolinska Institutet and Reumatikerförbundet. All the authors declared no competing interests.

Source: Lyne L et al. RMD Open. 2022;8:e001800 (Jan 5). Doi: 10.1136/rmdopen-2021-001800.

Key clinical point: In patients with rheumatoid arthritis (RA), sleep problems are more extensively related to pain and functional impairment than disease duration.

Major finding: The likelihood of having problems with at least 1 or more sleep domains increased slightly with the disease duration (adjusted odds ratio 1.04; 95% CI 1.02-1.07). High-grade pain and high Health Assessment Questionnaire (HAQ) level were associated with increased sleep problems by approximately 3-9-fold and 4-8-fold compared with low-grade pain and low HAQ level, respectively.

Study details: This was an analysis of 4,131 observations from 3,265 patients with newly diagnosed RA whose data on sleep over 12 years from diagnosis were available.

Disclosures: This study was supported by Karolinska Institutet and Reumatikerförbundet. All the authors declared no competing interests.

Source: Lyne L et al. RMD Open. 2022;8:e001800 (Jan 5). Doi: 10.1136/rmdopen-2021-001800.

Key clinical point: Fatigue was prevalent and persistent in patients with early rheumatoid arthritis (RA) with female gender, poor mental health, pain, and some functional abilities associated with greater fatigue.

Major finding: The age- and sex-standardized prevalence of fatigue and severe fatigue was 44% (95% CI 39%-50%) and 19% (95% CI 15%-23%), respectively, with little change observed over 3 years (ß −0.13; 95% CI −0.23 to −0.02). Female gender, worse pain, mental health, and functional ability were significantly associated with greater fatigue (P ≤ .05).

Study details: This was a multicenter cohort study involving 729 patients with RA with symptom duration of <2 years.

Disclosures: This work was funded by the Versus Arthritis Pain Centre. DF McWilliams and DA Walsh reported receiving funding and consultancy fees from various sources.

Source: Ifesemen OS et al. Rheumatology (Oxford). 2021;keab861 (Dec 27). Doi:  10.1093/rheumatology/keab947.

Key clinical point: Fatigue was prevalent and persistent in patients with early rheumatoid arthritis (RA) with female gender, poor mental health, pain, and some functional abilities associated with greater fatigue.

Major finding: The age- and sex-standardized prevalence of fatigue and severe fatigue was 44% (95% CI 39%-50%) and 19% (95% CI 15%-23%), respectively, with little change observed over 3 years (ß −0.13; 95% CI −0.23 to −0.02). Female gender, worse pain, mental health, and functional ability were significantly associated with greater fatigue (P ≤ .05).

Study details: This was a multicenter cohort study involving 729 patients with RA with symptom duration of <2 years.

Disclosures: This work was funded by the Versus Arthritis Pain Centre. DF McWilliams and DA Walsh reported receiving funding and consultancy fees from various sources.

Source: Ifesemen OS et al. Rheumatology (Oxford). 2021;keab861 (Dec 27). Doi:  10.1093/rheumatology/keab947.

Key clinical point: Fatigue was prevalent and persistent in patients with early rheumatoid arthritis (RA) with female gender, poor mental health, pain, and some functional abilities associated with greater fatigue.

Major finding: The age- and sex-standardized prevalence of fatigue and severe fatigue was 44% (95% CI 39%-50%) and 19% (95% CI 15%-23%), respectively, with little change observed over 3 years (ß −0.13; 95% CI −0.23 to −0.02). Female gender, worse pain, mental health, and functional ability were significantly associated with greater fatigue (P ≤ .05).

Study details: This was a multicenter cohort study involving 729 patients with RA with symptom duration of <2 years.

Disclosures: This work was funded by the Versus Arthritis Pain Centre. DF McWilliams and DA Walsh reported receiving funding and consultancy fees from various sources.

Source: Ifesemen OS et al. Rheumatology (Oxford). 2021;keab861 (Dec 27). Doi:  10.1093/rheumatology/keab947.

Key clinical point: A longer interval between rituximab infusion and SARS-CoV-2 vaccine may elicit an optimal response in patients with rheumatoid arthritis (RA) taking rituximab, with a third vaccination dose given 6-9 months after rituximab, boosting the cellular response despite the absence of a noticeable serological response.

Major finding: The median time between the last rituximab infusion and the first vaccination dose was significantly longer in responders vs. nonresponders (267 days vs. 107 days; P < .0001). A third vaccine dose in patients with insufficient serological response to 2 doses induced T-cell responses in all patients assessed, despite serological response in only 16.3% of patients. No serious adverse events or deaths were reported.

Study details: A prospective cohort study, Nor-vaC included patients with RA taking rituximab (n = 90) and healthy controls (n = 1,114) who received 2 or 3 doses of SARS-CoV-2 vaccines.

Disclosures: The study was funded by the Coalition for Epidemic Preparedness Innovations, Research Council of Norway COVID, and others. Several authors reported receiving speaker/consulting fees or grants/financial support from various sources.

Source: I Jyssum et al. Lancet Rheumatol. 2021 (Dec 23). Doi: 10.1016/S2665-9913(21)00394-5.

Key clinical point: A longer interval between rituximab infusion and SARS-CoV-2 vaccine may elicit an optimal response in patients with rheumatoid arthritis (RA) taking rituximab, with a third vaccination dose given 6-9 months after rituximab, boosting the cellular response despite the absence of a noticeable serological response.

Major finding: The median time between the last rituximab infusion and the first vaccination dose was significantly longer in responders vs. nonresponders (267 days vs. 107 days; P < .0001). A third vaccine dose in patients with insufficient serological response to 2 doses induced T-cell responses in all patients assessed, despite serological response in only 16.3% of patients. No serious adverse events or deaths were reported.

Study details: A prospective cohort study, Nor-vaC included patients with RA taking rituximab (n = 90) and healthy controls (n = 1,114) who received 2 or 3 doses of SARS-CoV-2 vaccines.

Disclosures: The study was funded by the Coalition for Epidemic Preparedness Innovations, Research Council of Norway COVID, and others. Several authors reported receiving speaker/consulting fees or grants/financial support from various sources.

Source: I Jyssum et al. Lancet Rheumatol. 2021 (Dec 23). Doi: 10.1016/S2665-9913(21)00394-5.

Key clinical point: A longer interval between rituximab infusion and SARS-CoV-2 vaccine may elicit an optimal response in patients with rheumatoid arthritis (RA) taking rituximab, with a third vaccination dose given 6-9 months after rituximab, boosting the cellular response despite the absence of a noticeable serological response.

Major finding: The median time between the last rituximab infusion and the first vaccination dose was significantly longer in responders vs. nonresponders (267 days vs. 107 days; P < .0001). A third vaccine dose in patients with insufficient serological response to 2 doses induced T-cell responses in all patients assessed, despite serological response in only 16.3% of patients. No serious adverse events or deaths were reported.

Study details: A prospective cohort study, Nor-vaC included patients with RA taking rituximab (n = 90) and healthy controls (n = 1,114) who received 2 or 3 doses of SARS-CoV-2 vaccines.

Disclosures: The study was funded by the Coalition for Epidemic Preparedness Innovations, Research Council of Norway COVID, and others. Several authors reported receiving speaker/consulting fees or grants/financial support from various sources.

Source: I Jyssum et al. Lancet Rheumatol. 2021 (Dec 23). Doi: 10.1016/S2665-9913(21)00394-5.

Key clinical point: Patients with psoriasis who showed ultrasound abnormalities in hand, knee, toe joints, and few other anatomical sites are more likely to progress to psoriatic arthritis (PsA).

Major finding: Hand joint power Doppler (PD) signals (grade 0 and ≥1), knee joint PD signals (grade 0 and ≥1), toe joint PD signals (grade 0 and ≥1), quadriceps tendon and patellar tendon enthesitis (all P < .001), wrist joint synovial thickening (grade 1-3; P = .001), and Achilles tendon and plantar aponeurosis enthesitis (P = .007) were all significant risk predictors for PsA.

Study details: Findings are from a cross-sectional study including 852 patients with psoriasis but without PsA, 261 patients with PsA, and 86 healthy volunteers who underwent an ultrasound examination.

Disclosures: This study was funded by West China Hospital, West China Precision Medicine Industrial Technology Institutes, and Sichuan Provincial Science and Technology Project. The authors declared no conflict of interests.

Source: Wang Y et al. Dermatol Ther (Heidelb). 2021 (Dec 19). Doi: 10.1007/s13555-021-00663-0.

Key clinical point: Patients with psoriasis who showed ultrasound abnormalities in hand, knee, toe joints, and few other anatomical sites are more likely to progress to psoriatic arthritis (PsA).

Major finding: Hand joint power Doppler (PD) signals (grade 0 and ≥1), knee joint PD signals (grade 0 and ≥1), toe joint PD signals (grade 0 and ≥1), quadriceps tendon and patellar tendon enthesitis (all P < .001), wrist joint synovial thickening (grade 1-3; P = .001), and Achilles tendon and plantar aponeurosis enthesitis (P = .007) were all significant risk predictors for PsA.

Study details: Findings are from a cross-sectional study including 852 patients with psoriasis but without PsA, 261 patients with PsA, and 86 healthy volunteers who underwent an ultrasound examination.

Disclosures: This study was funded by West China Hospital, West China Precision Medicine Industrial Technology Institutes, and Sichuan Provincial Science and Technology Project. The authors declared no conflict of interests.

Source: Wang Y et al. Dermatol Ther (Heidelb). 2021 (Dec 19). Doi: 10.1007/s13555-021-00663-0.

Key clinical point: Patients with psoriasis who showed ultrasound abnormalities in hand, knee, toe joints, and few other anatomical sites are more likely to progress to psoriatic arthritis (PsA).

Major finding: Hand joint power Doppler (PD) signals (grade 0 and ≥1), knee joint PD signals (grade 0 and ≥1), toe joint PD signals (grade 0 and ≥1), quadriceps tendon and patellar tendon enthesitis (all P < .001), wrist joint synovial thickening (grade 1-3; P = .001), and Achilles tendon and plantar aponeurosis enthesitis (P = .007) were all significant risk predictors for PsA.

Study details: Findings are from a cross-sectional study including 852 patients with psoriasis but without PsA, 261 patients with PsA, and 86 healthy volunteers who underwent an ultrasound examination.

Disclosures: This study was funded by West China Hospital, West China Precision Medicine Industrial Technology Institutes, and Sichuan Provincial Science and Technology Project. The authors declared no conflict of interests.

Source: Wang Y et al. Dermatol Ther (Heidelb). 2021 (Dec 19). Doi: 10.1007/s13555-021-00663-0.

Key clinical point: Patients with psoriatic arthritis (PsA) who received treatment with tofacitinib experienced mostly mild/moderate nonserious adverse events (AE), which persisted for a shorter duration and had a minimum effect on the continuation of tofacitinib treatment.

Major finding: In the first 3 months of treatment, the most frequent nonserious AEs were headache (incidence rate [IR] 16.9-39.2) and diarrhea (IR 15-17) and duration of such AEs was ≤4 weeks with none leading to permanent discontinuation of treatment.

Study details: Findings are from a post hoc analysis of phase 3 studies including 710 patients with active PsA who received 5 mg tofacitinib, 10 mg tofacitinib, or placebo and had a previous inadequate response to ≥1 conventional synthetic disease-modifying antirheumatic drug or ≥1 tumor necrosis factor inhibitor.

Disclosures: This study was funded by Pfizer. Five authors reported being employees and stockholders of AbbVie. The other authors reported ties with several sources including AbbVie.

Source: Dikranian A et al. Rheumatol Ther. 2021 (Dec 17). Doi: 10.1007/s40744-021-00405-w.

Key clinical point: Patients with psoriatic arthritis (PsA) who received treatment with tofacitinib experienced mostly mild/moderate nonserious adverse events (AE), which persisted for a shorter duration and had a minimum effect on the continuation of tofacitinib treatment.

Major finding: In the first 3 months of treatment, the most frequent nonserious AEs were headache (incidence rate [IR] 16.9-39.2) and diarrhea (IR 15-17) and duration of such AEs was ≤4 weeks with none leading to permanent discontinuation of treatment.

Study details: Findings are from a post hoc analysis of phase 3 studies including 710 patients with active PsA who received 5 mg tofacitinib, 10 mg tofacitinib, or placebo and had a previous inadequate response to ≥1 conventional synthetic disease-modifying antirheumatic drug or ≥1 tumor necrosis factor inhibitor.

Disclosures: This study was funded by Pfizer. Five authors reported being employees and stockholders of AbbVie. The other authors reported ties with several sources including AbbVie.

Source: Dikranian A et al. Rheumatol Ther. 2021 (Dec 17). Doi: 10.1007/s40744-021-00405-w.

Key clinical point: Patients with psoriatic arthritis (PsA) who received treatment with tofacitinib experienced mostly mild/moderate nonserious adverse events (AE), which persisted for a shorter duration and had a minimum effect on the continuation of tofacitinib treatment.

Major finding: In the first 3 months of treatment, the most frequent nonserious AEs were headache (incidence rate [IR] 16.9-39.2) and diarrhea (IR 15-17) and duration of such AEs was ≤4 weeks with none leading to permanent discontinuation of treatment.

Study details: Findings are from a post hoc analysis of phase 3 studies including 710 patients with active PsA who received 5 mg tofacitinib, 10 mg tofacitinib, or placebo and had a previous inadequate response to ≥1 conventional synthetic disease-modifying antirheumatic drug or ≥1 tumor necrosis factor inhibitor.

Disclosures: This study was funded by Pfizer. Five authors reported being employees and stockholders of AbbVie. The other authors reported ties with several sources including AbbVie.

Source: Dikranian A et al. Rheumatol Ther. 2021 (Dec 17). Doi: 10.1007/s40744-021-00405-w.